Patents by Inventor Donald Stuart Gann

Donald Stuart Gann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to bufalin prevent inhibition of Na/K ATPase and prolong survival in shock
    Patent number: 8062639
    Abstract: The present invention relates to compositions and methods of use thereof for treatment of clinical conditions manifested from and/or exacerbated by a decrease or an inhibition of Na/K ATPase activity. The invention relates to composition comprises monoclonal or polyclonal antibodies to bufalin and/or bufalin sulfate, or vaccination against bufalin and/or bufalin sulfate, which prevents or attenuates inhibition of Na/K ATPase activity thereby attenuating the adverse physiological effects of bufalin and/or bufalin sulfate inhibition. The invention also relates to methods of treating hemorrhagic, septic shock, cardiogenic shock, shock resulting from physical trauma, diabetes, mental depression, bipolar disorder and schizophrenia comprising administering a therapeutically effective amount of an bufalin monoclonal or polyclonal antibody.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: November 22, 2011
    Inventors: Donald Stuart Gann, Daniel Norman Darlington
  • Antibodies to bufadienolides prevent inhibition of Na/K ATPase and prolong survival in shock
    Publication number: 20090181031
    Abstract: The present invention relates to compositions and methods of use thereof for treatment of clinical conditions manifested from and/or exacerbated by a decrease or an inhibition of Na/K ATPase activity. The invention relates to composition comprises monoclonal or polyclonal antibodies to bufalin and/or bufalin sulfate, or vaccination against bufalin and/or bufalin sulfate, which prevents or attenuates inhibition of Na/K ATPase activity thereby attenuating the adverse physiological effects of bufalin and/or bufalin sulfate inhibition. The invention also relates to methods of treating hemorrhagic, septic shock, cardiogenic shock, shock resulting from physical trauma, diabetes, mental depression, bipolar disorder and schizophrenia comprising administering a therapeutically effective amount of an bufalin monoclonal or polyclonal antibody.
    Type: Application
    Filed: January 14, 2009
    Publication date: July 16, 2009
    Inventors: Donald Stuart Gann, Daniel Norman Darlington